A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation

Area of Science:

• Biotechnology
• Protein Engineering
• Pharmacology

Background:

• Recombinant interferon alpha-2 (IFN-alpha2) treats viral diseases and cancers but has a short half-life.
• Traditional poly(ethylene glycol) (PEG) modification of lysine residues yields heterogeneous mixtures with reduced specific activity.
• Site-specific modification is needed to improve IFN-alpha2's therapeutic profile.

Purpose of the Study:

• To assess the feasibility of creating site-specific, mono-PEGylated IFN-alpha2 analogues.
• To engineer IFN-alpha2 with an unpaired cysteine for targeted PEGylation.
• To evaluate the bioactivity and pharmacokinetics of the modified protein.

Main Methods:

• Engineered IFN-alpha2 cysteine analogues expressed in E. coli and purified.
• In vitro bioactivity assessed using a human Daudi cell line growth inhibition assay.
• Site-specific PEGylation achieved using maleimide-PEG reagents, followed by pharmacokinetic studies in rats.

Main Results:

• Several cysteine analogues maintained high in vitro bioactivity.
• The PEG-Q5C analogue, modified with 20- and 40-kDa PEGs, retained significant bioactivity.
• PEG-Q5C conjugates exhibited 20-fold and 40-fold longer half-lives, respectively, compared to native IFN-alpha2.

Conclusions:

• Site-specific PEGylation via introduced cysteine residues is a viable strategy for developing long-acting IFN-alpha2.
• This approach yields mono-PEGylated IFN-alpha2 with high specific activity and improved pharmacokinetic properties.
• The engineered PEG-Q5C analogue represents a promising candidate for enhanced IFN-alpha2 therapeutics.